Search Press releases Keywords From To 4 Apr 2024 FDA Accepts Supplemental Biologics License Applications for BIMZELX[®] (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations Read More 29 Mar 2024 Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees Read More 22 Mar 2024 UCB receives positive CHMP opinion for BIMZELX[®]▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa Read More 15 Mar 2024 UCB announces changes on Board of Directors Read More 13 Mar 2024 UCB successfully completes institutional Eurobond issue Read More 9 Mar 2024 First presentation of four-year BIMZELX[®](bimekizumab-bkzx) data showed long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis Read More Pagination First page Previous page Previous … Page 9 Page 10 Page 11 Page 12 Current page 13 Page 14 Page 15 Page 16 Page 17 … Page 13 of 73 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
